SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...
Medpage Today on MSN3d
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart FailureCHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
On the primary endpoints of the study, combined cardiovascular mortality and worsening heart failure events (α = 0.04) were ...
News Medical on MSN1d
Tirzepatide lowered risk of worsening heart failure and CVD death for obese adultsIn the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...
Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...
"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...
Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...
GlobalData on MSN19h
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEFThe trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
In an international trial of 713 adults in nine countries including the U.S. called SUMMIT, participants with heart failure with ...
(RTTNews) - Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly lowered the risk of worsening heart failure events in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback